Vertex Pharmaceuticals | Home
WEBVertex Pharmaceuticals invests in scientific innovation to create transformative medicines for people with serious diseases.
Vertex Pharmaceuticals - Wikipedia
WEBVertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.
Our approved medicines - Vertex
WEBInformation about Vertex Pharmaceuticals' approved medicines.
Experimental pain drug may offer alternative to opioids for acute …
WEBJan 30, 2024 · The medicine from Vertex Pharmaceuticals, dubbed VX-548, was superior to a placebo in relieving pain after two kinds of surgery: abdominoplasty – also known as a tummy tuck – and...
Experimental Drug Cuts Off Pain at the Source, Company Says
WEBJan 30, 2024 · Vertex Pharmaceuticals of Boston announced Tuesday that it had developed an experimental drug that relieves moderate to severe pain, blocking pain signals before they can get to the...
‘A game-changer’: How Vertex delivered on cystic fibrosis - STAT
WEBOct 23, 2019 · Trikafta, a combination of three medicines, including Kalydeco, can help 90% of cystic fibrosis patients. That leaves 10% without a new treatment. Trikafta has also made Vertex one of the most...
Vertex Announces FDA Acceptance of New Drug Application for …
WEBJul 30, 2024 · Suzetrigine has the potential to be the first new class of medicine to treat acute pain in over twenty years. The FDA has granted suzetrigine priority review and assigned a Prescription Drug User Fee Act (PDUFA) target …
Press Release - Vertex Pharmaceuticals Newsroom
WEBJun 21, 2024 · Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease, and transfusion-dependent beta ...
Vertex and CRISPR Therapeutics Announce US FDA Approval of …
WEBDec 8, 2023 · Vertex has submitted a BLA to the U.S. FDA for the potential use of CASGEVY for patients 12 years and older with TDT and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 30, 2024.
Vertex developed a CRISPR cure. Now it wants a pill to treat sickle ...
WEBDec 15, 2023 · The company that just got approval to sell the first gene-editing treatment in history, for sickle-cell disease, is already looking for an ordinary drug that could take its place.